Applications overview: where developmental and stem cell science is applied today

Reading time: 7 minutes

The previous articles in this series described the biology, cell types, methods, and manufacturing standards that underpin stem cell science. This article turns to what all of that is for: the applications. Where is developmental and stem cell science being put to work, how far has each application progressed, and what limits further progress?

The purpose is not to catalogue every project in the field. It is to give technology developers, assessors, and investors a working map of the application landscape so they can see where their tools, products, or funding decisions fit.

Disease modelling

Before stem cell science can treat a disease, it must model one. Disease modelling uses patient-derived cells, most commonly iPSCs, to recreate aspects of a disease in the laboratory. Cells collected from circulating blood or a skin biopsy (just two of the more common sources) from a patient with a genetic condition can be reprogrammed to iPSCs, then differentiated into the affected cell type, producing cells that carry the patient's own disease-causing mutation in a context where the disease phenotype can be studied [1].

This approach has been applied to inheritable forms of neurological conditions that includes Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, cardiac diseases (long QT syndrome, hypertrophic cardiomyopathy), metabolic disorders, and many others. Alternatively, specific DNA mutations associated with these can be genetically engineered into a common cell line. Organoid models have extended this further, enabling the study of disease in three-dimensional tissue contexts that better reflect human organ architecture [2].

The value for drug development is significant. Patient-derived or genetically engineered models allow compounds to be tested on human cells carrying the actual disease mutation, rather than on animal models that may not faithfully reproduce human pathology. Several pharmaceutical companies now incorporate iPSC-based disease models into their screening pipelines [1,3].

The limitations are also significant. Not all diseases produce a clear phenotype in a dish or are known to be associated with specific mutations. Diseases of ageing are particularly difficult to model using cells that have been reprogrammed to a rejuvenated state. The maturity of iPSC-derived cells, which frequently resemble fetal rather than adult tissue, constrains their relevance to adult-onset diseases. Reproducibility between laboratories remains a persistent concern [1].

Cell therapy

Cell therapy is the application that attracts the most public attention and investment. The principle is to replace, repair, or supplement damaged or dysfunctional cells with functional ones derived from stem cells.

Haematopoietic stem cell transplantation for blood cancers and immune deficiencies has been an established clinical practice for decades and remains the most mature example. Beyond this, pluripotent stem cell-derived therapies are in clinical development for macular degeneration (retinal pigment epithelium), Parkinson's disease (dopaminergic neurons), type 1 diabetes (pancreatic islet cells), heart failure (cardiomyocytes), and spinal cord injury (oligodendrocyte progenitors), among others [4,5].

Mesenchymal stromal cell therapies, typically using adult-tissue-derived MSCs, have been tested in hundreds of clinical trials for conditions including graft-versus-host disease, osteoarthritis, and cardiac repair, with mixed results that reflect the challenges of standardisation and potency discussed in earlier articles [6].

The barriers to broader clinical adoption are substantial. Manufacturing at clinical scale while maintaining quality and consistency is difficult and expensive. Demonstrating efficacy in controlled trials has proven harder than early enthusiasm suggested. Immune rejection remains a concern for allogeneic (donor-derived) products. Safety considerations, including the risk of tumour formation from residual undifferentiated cells, require rigorous characterisation and long-term follow-up [4]. Regulatory pathways for cell therapies are more complex than for conventional drugs, reflecting the inherent variability of living products.

Reproduction and breeding

Developmental and stem cell biology has a long history of application in animal reproduction. In vitro fertilisation, embryo transfer, and somatic cell nuclear transfer (cloning) were all developed in the context of livestock breeding and reproductive science before being applied to other fields [7].

These techniques remain relevant for animal breeding, where they enable the propagation of genetically valuable animals and the production of genetically modified livestock for agricultural or biomedical purposes. Our own work at the Roslin Institute on cloning across multiple species contributed to this domain directly [8].

In human medicine, assisted reproductive technologies including IVF and preimplantation genetic testing rely on an understanding of early embryo development that is rooted in developmental biology. Advances in stem cell science are now informing human reproductive medicine further, through the development of in vitro gametogenesis (the generation of eggs or sperm from pluripotent stem cells), which has been achieved in mice and is the subject of active research in humans [9].

Species preservation

Habitat loss is driving species extinction at rates far above the natural background. Traditional conservation measures, important as they are, cannot alone prevent the loss of species for which population sizes have fallen below genetically viable thresholds [10].

Stem cell science offers a complementary approach. The creation of biobanks preserving cells and tissues from endangered species provides a reservoir of genetic material that could, in principle, be used to generate gametes, embryos, or even animals through somatic cell nuclear transfer or in vitro gametogenesis. iPSC technology has been applied to cells from the northern white rhinoceros, of which only two females remain alive, and to several other endangered species [10,11].

The challenges are formidable. Species-specific biological knowledge is scarce for most endangered animals. Reprogramming and differentiation protocols developed in mice or humans do not transfer directly. Access to eggs for nuclear transfer or IVF is severely limited. The ethical dimensions of intervening in the biology of endangered species also requires careful consideration [10].

This is one of the applications where the biology itself is the enabling technology, and where the gap between what is known in laboratory and domesticated species and what is needed for conservation species defines the central scientific challenge.

Food production

Cell-based or cultured meat uses animal cells grown in bioreactors to produce muscle and fat tissue for human consumption, without raising and slaughtering animals. The approach draws on techniques developed in stem cell science, including cell culture, directed differentiation, and tissue engineering [12].

The field has attracted substantial investment and media attention since the first cultured meat prototype was presented in 2013. Since then, multiple companies have pursued regulatory approval for cultured meat products, and Singapore became the first country to approve their sale in 2020. Regulatory approvals have since followed in other jurisdictions [12].

The technical challenges are significant and overlap with those in cell therapy manufacturing: achieving consistent large-scale expansion, reducing the cost of culture media (which can represent a large fraction of production cost), replacing animal-derived components, and engineering tissue structures that replicate the texture and nutritional profile of conventional meat [13].

For stem cell science, the cultured meat industry represents both a potential market for ancillary technologies and a forcing function for manufacturing innovation. The volumes required for food production are orders of magnitude larger than for therapeutic applications, which creates demand for scalable, cost-effective cell culture systems that do not yet exist [13].

Ageing and rejuvenation

The capacity to heal and regenerate diminishes with age. This decline is associated with several hallmarks of ageing, including stem cell exhaustion, epigenetic dysregulation, mitochondrial dysfunction, and cellular senescence [14].

Developmental and stem cell biology is relevant to ageing research because the developing and stem cells of early life hold information about the mechanisms of tissue formation and renewal. Cellular reprogramming, in particular partial reprogramming using Yamanaka factors to reverse aspects of cellular ageing without full dedifferentiation, has shown promise in rejuvenating aged cells in laboratory settings [15].

This is among the most speculative and rapidly growing application areas. Investment in longevity and rejuvenation science has increased sharply. Clinical translation remains distant for most approaches, and the gap between promising laboratory results and safe, effective treatments is substantial. The field needs rigorous assessment frameworks to distinguish interventions with genuine potential from those that are oversold.

What limits progress

Across all these applications, several recurring themes emerge. The biology is high-dimensional and difficult to standardise. The gap between research-grade and clinical or commercial-grade processes is large. Characterisation tools are not yet adequate to predict functional performance. Manufacturing at scale while maintaining quality is expensive and technically demanding.

These shared challenges define the domain in which ancillary technologies operate. Pillar 2 examines why many of these ancillary technologies fail, addressing reproducibility, scale-up, characterisation gaps, regulatory transition, and toolchain fragmentation as specific failure modes. The next and final article in this Pillar 1 series introduces a framework for thinking about whether the technologies addressing these challenges are themselves sustainable: not just whether they work, but whether they are ethical, affordable, scalable, effective, safe, and ecologically responsible.

References

[1] Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017;16(2):115-130. DOI: 10.1038/nrd.2016.245

[2] Clevers H. Modeling development and disease with organoids. Cell. 2016;165(7):1586-1597. DOI: 10.1016/j.cell.2016.05.082

[3] Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019;20(7):377-388. DOI: 10.1038/s41576-019-0100-z

[4] Yamanaka S. Pluripotent stem cell-based cell therapy: promise and challenges. Cell Stem Cell. 2020;27(4):523-531. DOI: 10.1016/j.stem.2020.09.014

[5] Barker RA, Parmar M, Studer L, Takahashi J. Human trials of stem cell-derived dopamine neurons for Parkinson's disease: dawn of a new era. Cell Stem Cell. 2017;21(5):569-573. DOI: 10.1016/j.stem.2017.09.014

[6] Galipeau J, Sensebe L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. DOI: 10.1016/j.stem.2018.05.004

[7] Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. Nature. 1997;385(6619):810-813. DOI: 10.1038/385810a0

[8] Wilmut I, Beaujean N, De Sousa PA, Dinnyes A, King TJ, Paterson LA, Wells DN, Young LE. Somatic cell nuclear transfer. Nature. 2002;419(6907):583-586. DOI: 10.1038/nature01079

[9] Hayashi K, Ohta H, Kurimoto K, Aramaki S, Saitou M. Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. Cell. 2011;146(4):519-532. DOI: 10.1016/j.cell.2011.06.052

[10] Hutchinson AM, Appeltant R, Burdon T, Bao Q, Bargaje R, Bodnar A, Chambers S, Comizzoli P, Cook L, Endo Y, Harman B, Hayashi K, Hildebrandt T, Korody ML, Lakshmipathy U, Loring JF, Munger C, Ng AHM, Novak B, Onuma M, Ord S, Paris M, Pask AJ, Pelegri F, Pera M, Phelan R, Rosental B, Ryder OA, Sukparangsi W, Sullivan G, Tay NL, Traylor-Knowles N, Walker S, Weberling A, Whitworth DJ, Williams SA, Wojtusik J, Wu J, Ying QL, Zwaka TP, Kohler TN. Advancing stem cell technologies for conservation of wildlife biodiversity. Development. 2024 Oct 15;151(20):dev203116. doi: 10.1242/dev.203116.

[11] Korody ML, Ford SM, Nguyen TD, Pivaroff CG, Valiente-Alandi I, Peterson SE, Ryder OA, Loring JF. Rewinding Extinction in the Northern White Rhinoceros: Genetically Diverse Induced Pluripotent Stem Cell Bank for Genetic Rescue. Stem Cells Dev. 2021 Feb;30(4):177-189. doi: 10.1089/scd.2021.0001.

[12] Martins B, Bister A, Dohmen RGJ, et al. Advances and challenges in cell biology for cultured meat. Annu Rev Anim Biosci. 2024;12:345-368. DOI: 10.1146/annurev-animal-021022-055132

[13] Post MJ, Levenberg S, Kaplan DL, et al. Scientific, sustainability and regulatory challenges of cultured meat. Nat Food. 2020;1(7):403-415. DOI: 10.1038/s43016-020-0112-z

[14] Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243-278. DOI: 10.1016/j.cell.2022.11.001

[15] Gill D, Parry A, Santos F, et al. Multi-omic rejuvenation of human cells by maturation phase transient reprogramming. eLife. 2022;11:e71624. DOI: 10.7554/eLife.71624

About StemCells.Help

StemCells.Help is an advisory consultancy that aids innovation and real-world impact of life science applications built on developmental and stem cell biology. Founded by Dr Paul De Sousa, it draws on over four decades of experience spanning early embryo development, animal cloning, pluripotent stem cell manufacturing, and technology commercialisation. If you build tools for these domains or work in an emerging application where the biology is the enabling technology, StemCells.Help can provide experienced scientific counsel to ground your decisions. To discuss your needs, talk to Paul.

ORCID: 0000-0003-0745-2504

Web: stemcells.help